needle magazine

A needle magazine for holding a plurality of injection needles ( 50 ) is described. The needle magazine comprises a first opening adapted to receive the device fluid access portion ( 120 ) of a medical delivery device. Each needle ( 50 ) is selectively moveable from a respective storage position not aligned with said first opening into a needle mounting position aligned with said first opening. The needle magazine further comprises needle positioning means ( 41 ). configured to alter the mutual position between a needle selected from said plurality of needles ( 50 ) relative to a neighbour needle when said selected needle moves from its storage position to the needle mounting position.

TILTABLE SAFETY NEEDLE

A shielded needle assembly for a drug delivery device in which a needle cannula () tilts once the needle assembly is removed from the drug delivery device whereby a non-patient end () of a needle cannula () abuts an inside surface of the needle hub () and a patient end () of the same needle cannula () blocks the axial movement of the shield (). 1. A needle assembly for a drug delivery device comprising{'b': 1', '30, 'A needle hub () attachable to the drug delivery device (),'}{'b': 20', '1', '21', '22, 'A needle cannula () secured to the hub () and having a patient end () and a non-patient end (),'}{'b': 50', '21', '20, 'A telescopically movable shield () adapted to at least partially cover the patient-end () of the needle cannula (),'}{'b': 20', '20', '20', '21', '20', '50', '21', '20, 'Characterized in that, the needle cannula () has a first position in which the needle cannula () is substantial parallel aligned with a centre axis (X) of the needle assembly, and a second position in which the needle cannula () deflects from the first position and in which second position the patient end () of the needle cannula () engages the shield () whereby exposure of the patient end () of the needle cannula () is prevented.'}211020. A needle assembly for a drug delivery device according to claim 1 , in which the needle hub () comprises a bridge part () holding the needle cannula ().31011. A needle assembly for a drug delivery device according to claim 2 , in which the bridge part () has a free-floating leg ().4114. A needle assembly for a drug delivery device according to claim 3 , in which the free-floating leg () is supported by a release part ().541. A needle assembly for a drug delivery device according to claim 4 , in which the release part () is a radially movable part of the hub ().61014. A needle assembly for a drug delivery device according to claim 5 , in which the bridge part () is provided with a film hinge ().76010. A needle assembly for a drug delivery device ...

OSTOMY APPLIANCE COUPLING SYSTEM AND AN OSTOMY APPLIANCE

According to an embodiment of the invention, an ostomy appliance coupling system is disclosed. The system comprises a wafer part having a rise extending away from a body surface to form a guide means and a shallow landing zone; a pouch part having a guide adapted to engage with the landing zone in a desired location relative to the guide means; and an adhesive layer recessed within the guide and adapted to adhere to the landing zone. 1. An ostomy appliance coupling system , comprising:a wafer part having a rise extending away from a body surface to form a guide means and a shallow landing zone;a pouch part having a guide adapted to engage with the landing zone in a desired location relative to the guide means; andan adhesive layer recessed within the guide and adapted to adhere to the landing zone.2. The system according to claim 1 , wherein the guide comprises an inner edge guide and an outer edge guide claim 1 , the adhesive layer being recessed between the inner edge guide and outer edge guide.3. The system according to claim 1 , further comprising:a central wafer part opening in the wafer part to surround a stoma;a central pouch part opening in the pouch part adapted to align with the central wafer part opening;an ostomy pouch having an ostomy pouch opening and attached to a distal pouch surface of the pouch part such that the ostomy pouch opening is in alignment with the central pouch part opening; andwherein, the guide means and guide provide positioning of the pouch part on the wafer part.4. The system according to claim 3 , wherein the positioning comprises placing the pouch part on the wafer part in a desired orientation and aligning the central pouch part opening with the central wafer part opening.5. The system according to claim 1 , wherein the ostomy pouch is sealed to the distal pouch surface by a sealing method claim 1 , such as thermal welding.6. The system according to claim 1 , wherein:the wafer part and the pouch part are selected from annular ...

Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors

A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

WAVE POWER DEVICE

The present invention relates to a wave power device for extracting energy from water waves. The waver power device comprise a reference structure and effectors moving relative to the reference structure. The effectors are connected 5 to two hydraulic rams, symmetrically positioned around each effector. The hydraulic rams have an effective hydraulic area which is stepwise increased as the length of the hydraulic rams are compressed and stepwise increased as the length of the hydraulic rams are increased. 214214314414332124. A wave power device according to claim 1 , wherein the sections ( claim 1 , claim 1 , ) of each hydraulic ram () comprise sealing means () claim 1 , to ensure that no water can flow into or out of the hydraulic ram by other means than through the inlet () and outlet () respectively.32727. A wave power device according to claim 1 , wherein the stepwise decrease or increase of the effective hydraulic area of each hydraulic ram claim 1 , is being controlled by locking means () claim 1 , wherein the locking means () are based on magnetic locking means or mechanical locking means or hydraulic locking means or a combination thereof.411. A wave power device according to claim 1 , wherein the substantially stationary member is arranged horizontally in the water claim 1 , in a way so the effector () moves along a horizontal length axis claim 1 , when wave forces are acting on it.5242452. A wave power device according to claim 1 , wherein the substantially stationary member () is kept stationary by at least two mooring chains () claim 1 , preferably arranged in each end of the substantially stationary member () claim 1 , wherein each mooring chain () is either connected to an anchor () or fastened to the bottom surface below the substantially stationery member () or fastened to the shore.632. A wave power device according to claim 1 , wherein the substantially stationary member is kept flowing in the water claim 1 , by at least two buoys () claim 1 , ...

Antimalarial Hexahydropyrimidine Analogues

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. 2. A compound as claimed in wherein Z represents phenyl claim 1 , naphthyl claim 1 , 2 claim 1 ,3-dihydroindolyl claim 1 , 2 claim 1 ,3-dihydrobenzoxazinyl claim 1 , pyrazolyl claim 1 , pyrazolo[1 claim 1 ,5-a]pyridinyl claim 1 , pyrazolo-[3 claim 1 ,4-b]pyridinyl claim 1 , indazolyl claim 1 , imidazo[1 claim 1 ,2-a]pyridinyl claim 1 , imidazo[1 claim 1 ,5-a]pyridinyl claim 1 , imidazo-[4 claim 1 ,5-b]pyridinyl claim 1 , [1 claim 1 ,2 claim 1 ,4]triazolo[1 claim 1 ,5-a]pyridinyl claim 1 , pyridinyl claim 1 , quinolinyl claim 1 , isoquinolinyl claim 1 , pyridazinyl claim 1 , pyrimidinyl or pyrazinyl claim 1 , any of which groups may be optionally substituted by one claim 1 , two or three substituents independently selected from halogen claim 1 , cyano claim 1 , Calkyl claim 1 , difluoromethyl claim 1 , trifluoromethyl claim 1 , trifluoroethyl claim 1 , cyclopropyl claim 1 , cyclobutyl claim 1 , cyanocyclobutyl claim 1 , phenyl claim 1 , azetidinyl claim 1 , oxopyrrolidinyl claim 1 , morpholinyl claim 1 , oxazolyl claim 1 , methyloxadiazolyl claim 1 , triazolyl claim 1 , methyltetrazolyl claim 1 , oxo claim 1 , Calkoxy claim 1 , difluoromethoxy claim 1 , trifluoromethoxy claim 1 , difluoroethoxy claim 1 , trifluoroethoxy claim 1 , phenoxy claim 1 , methylenedioxy claim 1 , difluoromethylenedioxy claim 1 , Calkylsulfonyl claim 1 , di(C)alkylamino claim 1 , Calkylcarbonyl claim 1 , Calkoxycarbonyl and di(C)alkylsulfoximino.4. A compound as claimed in wherein Rrepresents hydrogen claim 3 , halogen claim 3 , cyano claim 3 , Calkyl claim 3 , trifluoromethyl claim 3 , ...

Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity

A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. A compound as claimed in wherein A represents C—R claim 1 , B represents C—R claim 1 , and D represents C—R.5. A compound as claimed in as herein specifically disclosed in any one of the Examples.6. (canceled)7. (canceled)8. (canceled)9. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in association with a pharmaceutically acceptable carrier.10. A pharmaceutical composition as claimed in further comprising an additional pharmaceutically active ingredient.11. (canceled)12. (canceled)13. A method for the treatment and/or prevention of disorders for which the administration of a modulator of TNFα function is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt thereof.14. A method for the treatment and/or prevention of an inflammatory or autoimmune disorder claim 1 , a neurological or neurodegenerative disorder claim 1 , pain or a nociceptive disorder claim 1 , a cardiovascular disorder claim 1 , a metabolic disorder claim 1 , an ocular disorder claim 1 , or an oncological disorder claim 1 , which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt thereof. The present invention relates to a class of fused ...

Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity

A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. The compound as claimed in wherein Y represents phenyl claim 1 , which group may be optionally substituted by one or more substituents.7. The compound as claimed in any one of the preceding claims wherein E represents —CH—.8. The compound as claimed in wherein Rrepresents —CONRR claim 1 , in which Rand Rare as defined in ; or Rrepresents heteroaryl claim 1 , which group may be optionally substituted by one or more substituents.9. The compound as claimed in wherein Rrepresents difluoromethoxy.10. A compound as herein specifically disclosed in any one of the Examples.11. (canceled)12. (canceled)13. (canceled)14. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , in association with a pharmaceutically acceptable carrier.15. The pharmaceutical composition as claimed in further comprising an additional pharmaceutically active ingredient.16. (canceled)17. (canceled)18. A method for the treatment and/or prevention of disorders for which the administration of a modulator of TNFα function is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof.19. A method for the treatment and/or prevention of an inflammatory or autoimmune disorder claim 1 , a ...

Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity

A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. The compound as claimed in wherein E represents —CH— or —CH(CH)—.3. The A-compound as claimed in wherein Q represents —O— or —C(R)(R).4. The compound as claimed in wherein X represents a covalent bond or a group of formula —C(R)(R)—.7. The compound as claimed in wherein Y represents pyrazolyl claim 1 , isoxazolyl claim 1 , imidazolyl claim 1 , imidazo[1 claim 1 ,2-a]pyridinyl claim 1 , imidazo[1 claim 1 ,2-a]-pyrazinyl claim 1 , triazolyl claim 1 , pyridinyl claim 1 , pyridazinyl or pyrimidinyl claim 1 , any of which groups may be optionally substituted by one claim 1 , two or three substituents independently selected from halogen claim 1 , Calkyl claim 1 , halo(C)alkyl claim 1 , Calkoxy claim 1 , (C)alkoxy(C)alkoxy(C)alkyl claim 1 , Calkylthio claim 1 , Calkylsulfonyl claim 1 , Calkylsulfonylphenyl claim 1 , hydroxy(C)alkyl claim 1 , cyano claim 1 , oxetanyloxy(C)alkyl claim 1 , (C)alkylheteroaryl claim 1 , (C)alkoxyheteroaryl claim 1 , hydroxy(C)alkyl-heteroaryl claim 1 , oxoheteroaryl and morpholinylheteroaryloxy(C)alkyl.8. The compound as claimed in wherein Z represents aryl or heteroaryl claim 1 , either of which groups may be optionally substituted by one or more substituents.9. The compound as claimed in wherein Z represents phenyl claim 1 , pyrrolidinyl claim 1 , dihydrobenzoisothiazolyl claim 1 , piperidinyl claim 1 , 1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydroquinolinyl claim 1 , 1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydroisoquinolinyl claim 1 , 1 claim 1 ,2 claim 1 ,3 claim 1 ,6-tetrahydropyridinyl ...

TNF -Alpha Modulating Benzimidazoles

A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. A compound of formula (I) as depicted in claim 1 , or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , whereinY represents phenyl or thiazolyl, either of which groups may be optionally substituted by one or more substituents;{'sup': '1', 'sub': '3-7', 'Rrepresents heteroaryl or (C)heterocycloalkyl-heteroaryl-, either of which groups may be optionally substituted by one or more substituents; and'}{'sup': 2', '3, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'E, Q, Z, Rand Rare as defined in .'}4. A compound as claimed in wherein Rrepresents heteroaryl or (C)heterocycloalkyl-heteroaryl- claim 3 , either of which groups may be optionally substituted by one or more substituents.6. A compound as claimed in wherein Rrepresents hydroxy(C)alkyl.8. A compound as claimed in wherein Rrepresents hydrogen or hydroxy.9. A compound as claimed in wherein E represents{'sub': 2', '3, '—CH— or —CH(CH)—.'}10. A compound as claimed in wherein Rrepresents hydrogen or fluoro.11. A compound as claimed in wherein Rrepresents difluoromethoxy.12. A compound as herein specifically disclosed in any one of Examples 2 claim 3 , 3A claim 3 , 3B claim 3 , 5-531 claim 3 , 532-540 claim 3 , and 541-1105.13. (canceled)14. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , in ...

ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES

A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propagation of the parasite in human blood, are beneficial as pharmaceutical agents, especially in the treatment of malaria. 3. A compound as claimed in wherein Rrepresents hydrogen claim 2 , halogen claim 2 , cyano claim 2 , trifluoromethyl or trifluoromethoxy.4. A compound as claimed in wherein Rrepresents hydrogen claim 2 , halogen claim 2 , cyano claim 2 , trifluoromethyl claim 2 , Calkoxy claim 2 , trifluoromethoxy or Calkylsulfonyl.5. A compound as claimed in wherein Rrepresents Ccycloalkyl or Cheterocycloalkyl claim 1 , either of which groups may be optionally substituted by one claim 1 , two or three substituents independently selected from halogen and Calkyl.8. A compound as claimed in claim 1 , wherein Z represents phenyl claim 1 , naphthyl claim 1 , furyl claim 1 , benzofuryl claim 1 , pyrrolyl claim 1 , indolyl claim 1 , pyrazolyl claim 1 , imidazolyl claim 1 , imidazo[1 claim 1 ,2-a]pyridinyl claim 1 , imidazo[1 claim 1 ,5-a]pyridinyl claim 1 , imidazo[1 claim 1 ,2-a]pyrazinyl claim 1 , oxadiazolyl claim 1 , [1 claim 1 ,2 claim 1 ,4]-triazolo[4 claim 1 ,3-a]pyridinyl claim 1 , tetrazolo[1 claim 1 ,5-a]pyridinyl claim 1 , pyridinyl claim 1 , quinolinyl claim 1 , naphthyridinyl claim 1 , pyridazinyl claim 1 , cinnolinyl claim 1 , pyrimidinyl claim 1 , pyrazinyl or quinoxalinyl claim 1 , any of which groups may be optionally substituted by one claim 1 , two or three substituents independently selected from halogen claim 1 , cyano claim 1 , Calkyl claim 1 , trifluoromethyl claim 1 , Calkynyl claim 1 , cyclopropyl claim 1 , Calkoxy claim 1 , difluoromethoxy claim 1 , trifluoromethoxy claim 1 , trifluoroethoxy claim 1 , methylenedioxy claim 1 , Calkylsulfonyl claim 1 , di(C)alkylamino claim 1 , morpholinyl claim 1 , pyrazolyl claim ...

Imidazopyridine Derivatives as Modulators of TNF Activity

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. A compound as claimed in claim 1 , whereinY represents phenyl or thiazolyl, either of which groups may be optionally substituted by one or more substituents;{'sup': '1', 'sub': '3-7', 'Rrepresents heteroaryl or (C)heterocycloalkyl-heteroaryl-, either of which groups may be optionally substituted by one or more substituents; and'}{'sup': 2', '3', '4, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'E, Q, Z, R, Rand Rare as defined in .'}4. A compound as claimed in wherein Rrepresents heteroaryl or (C)heterocycloalkyl-heteroaryl- claim 3 , either of which groups may be optionally substituted by one or more substituents.6. A compound as claimed in wherein Rrepresents hydroxy(C)alkyl.9. A compound as claimed in wherein Rrepresents hydrogen or hydroxy.10. A compound as claimed in wherein E represents —CH— or —CH(CH)—.11. A compound as claimed in wherein Rrepresents hydrogen or fluoro.12. A compound as claimed in wherein Rrepresents difluoromethoxy.13. A compound as herein specifically disclosed in any one of the Examples.14. (canceled)15. (canceled)16. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , in association with a pharmaceutically acceptable carrier.17. A pharmaceutical composition as claimed in further comprising an additional pharmaceutically active ingredient.18. A method for the treatment and/or prevention of disorders for which the ...

Purine Derivatives As Modulators of TNF Activity

A series of substituted purine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. The compound as claimed in wherein Y represents phenyl claim 1 , which group may be optionally substituted by one or more substituents.4. The compound as claimed in wherein Rrepresents Cheterocycloalkyl claim 3 , which group may be optionally substituted by one or more substituents.8. The compound as claimed in wherein E represents —CH—.9. A compound as herein specifically disclosed in any one of the Examples.10. (canceled)11. (canceled)12. (canceled)13. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , in association with a pharmaceutically acceptable carrier.14. The pharmaceutical composition as claimed in further comprising an additional pharmaceutically active ingredient.15. (canceled)16. (canceled)17. A method for the treatment and/or prevention of disorders for which the administration of a modulator of TNFα function is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof.18. A method for the treatment and/or prevention of an inflammatory or autoimmune disorder claim 1 , a neurological or neurodegenerative disorder claim 1 , pain or a nociceptive disorder claim 1 , a cardiovascular disorder claim 1 , a ...

Tetrahydroimidazopyridine Derivatives As Modulators of TNF Activity

A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 2. The compound as claimed in wherein Y represents phenyl claim 1 , which group may be optionally substituted by one or more substituents.4. The compound as claimed in wherein E represents —CH—.5. The compound as claimed in wherein Rrepresents —SOR claim 1 , —CORor —COR claim 1 , in which Rand Rare as defined in ; or Rrepresents Calkyl claim 1 , which group may be optionally substituted by one or more substituents.6. A compound as herein specifically disclosed in any one of the Examples.7. (canceled)8. (canceled)9. (canceled)10. A pharmaceutical composition comprising a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof claim 1 , in association with a pharmaceutically acceptable carrier.11. The pharmaceutical composition as claimed in further comprising an additional pharmaceutically active ingredient.12. (canceled)13. (canceled)14. A method for the treatment and/or prevention of disorders for which the administration of a modulator of TNFα function is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or an N-oxide thereof claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , or a glucuronide derivative thereof claim 1 , or a co-crystal thereof.15. A method for the treatment and/or prevention of an inflammatory or autoimmune disorder claim 1 , a ...

IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS

A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria. 2. A compound as claimed in wherein Z represents indolyl claim 1 , pyrazolo[1 claim 1 ,5-a]pyridinyl claim 1 , indazolyl claim 1 , benzothiazolyl claim 1 , benzimidazolyl claim 1 , imidazo[1 claim 1 ,2-a]pyridinyl claim 1 , imidazo-[4 claim 1 ,5-b]pyridinyl or quinolinyl claim 1 , any of which groups may be optionally substituted by one claim 1 , two or three substituents independently selected from halogen claim 1 , cyano claim 1 , Calkyl claim 1 , difluoromethyl claim 1 , trifluoromethyl claim 1 , cyclopropyl claim 1 , cyclobutyl claim 1 , pyrrolidinyl claim 1 , morpholinyl claim 1 , methylpyrazolyl claim 1 , oxo claim 1 , hydroxy claim 1 , hydroxy(C)alkyl claim 1 , Calkoxy claim 1 , difluoromethoxy claim 1 , Calkylsulfonyl claim 1 , amino claim 1 , Calkylamino claim 1 , di(C)alkylamino claim 1 , di(C)alkylamino(C)alkyl claim 1 , benzylamino claim 1 , carboxy claim 1 , di(C)alkylaminocarbonyl and di(C)alkylaminosulfonyl.7. A compound as claimed in wherein Rrepresents hydrogen claim 1 , methyl claim 1 , ethyl or 2-hydroxyethyl.8. A compound as claimed in as herein specifically disclosed in any one of the Examples.9. (canceled)10. (canceled)11. A pharmaceutical composition comprising a compound of formula (I) as defined in or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.12. (canceled)13. A method for the treatment and/or prevention of malaria claim 1 , which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in or a pharmaceutically acceptable salt ...

COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF LOWE SYNDROME OR DENT DISEASE AND METHODS THEREFOR

Compounds, compositions and their use in the treatment or prevention of symptoms of Lowe Syndrome and Dent disease 2 are described, for instance, the use of such compounds in the treatment of Lowe Syndrome and Dent disease 2, or in the treatment or prevention of at least one symptom associated therewith. The compounds disclosed are of Formula I: 114-. (canceled)16. The method of claim 15 , wherein said compound is 2 claim 15 ,4 claim 15 ,6-trimethyl-N-(m-3-trifluoromethylphenyl)benzene sulfonamide or a solvate thereof.17. The method of claim 15 , for treating Lowe syndrome.18. The method of claim 15 , for treating Dent disease 2.20. The method of claim 19 , wherein said compound is 2 claim 19 ,4 claim 19 ,6-trimethyl-N-(m-3-trifluoromethylphenyl)benzene sulfonamide or a solvate thereof.21. The method of claim 15 , wherein said treatment comprises restoring normal cytokinesis or preventing cytokinetic failure in OCRL1 depleted cells in the subject.22. The method of claim 15 , wherein said treatment comprises restoring renal tubule endocytosis in the subject.24. The method of claim 23 , wherein said compound is 2 claim 23 ,4 claim 23 ,6-trimethyl-N-(m-3-trifluoromethylphenyl)benzene sulfonamide or a solvate thereof.25. The method of claim 23 , wherein said at least one symptom associated with Lowe syndrome is at least one selected from the group consisting of brain development damages claim 23 , congenital cataracts claim 23 , weak muscle tone claim 23 , and life-threatening kidney abnormalities.26. The method of claim 23 , wherein said at least one symptom associated with Lowe syndrome is at least one selected from the group consisting of cataracts claim 23 , glaucoma claim 23 , hypotonia claim 23 , mental retardation claim 23 , aminoaciduria claim 23 , phosphaturia claim 23 , and low-molecular-weight proteinuria.27. The method of claim 23 , wherein said at least one symptom associated with Dent disease 2 is at least one selected from the group consisting of ...

Pharmaceutical 6,5 Heterobicyclic Ring Derivatives

The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy. 7. A compound according to claim 1 , wherein R1 is ethyl-azabicyclo[3.2.0]heptane; or 2-substituted-5-azaspiro[3.4.]octane; or ethyl-2-methyl-pyrrolidine or (C4-7) cycloalkylamines including 3-substituted-N-methyl-cyclobutanamine and piperidine.8. A compound according to claim 7 , wherein R1 is 3-substituted-N-methyl-cyclobutanamine.9. A compound according to claim 7 , wherein R1 is 2-substituted-5-azaspiro[3.4.]octane.10. A compound according to claim 7 , wherein R1 is (C4-7) cycloalkylamines including 3-substituted-N-methyl-cyclobutanamine and piperidine.11. A compound according to claim 1 , wherein R2 is 1-substituted-4-aryl-piperazine or 1-substituted-4-heteroaryl-piperazine or 1-(4-substituted-aryl)piperazine or 1-(4-substituted-heteroaryl)piperazine or 1-substituted-4-aryl-piperidine or 1-substituted 4-heteroaryl-piperidine or 1-(4-substituted-aryl)piperidine or 1-(4-substituted-heteroaryl)piperidine with optional substitution on aryl claim 1 , heteroaryl claim 1 , piperazine or piperidine groups.12. A compound according to claim 11 , wherein R2 is 1-substituted-4-aryl-piperazine or 1-substituted-4-heteroaryl-piperazine claim 11 , 1-substituted-4-aryl-piperidine or 1-substituted-4-heteroaryl-piperidine.15. A compound according to claim 1 , which is selected from the group consisting of:6-[(3S)-3-methyl-4-(2-methylphenyl)piperazin-1-yl]-1-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrolo[2,3-b]pyridine;6-[(2S)-2-methyl-4-(2-methylphenyl)piperazin-1-yl]-1-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrolo[2,3-b]pyridine;6-{4-[2-(methylsulfonyl)phenyl]piperazin-1-yl}-1-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrolo[2,3-b]pyridine;6-[(2R)-2-methyl-4-(2-methylphenyl)piperazin-1-yl]-1-[2-(pyrrolidin-1-yl) ...

Separation of alkenes and alkanes

Ethene is separated from a gas mixture containing ethane by a pressure swing adsorption process carried out at a temperature in the range of about 50 to about 200° C., wherein the adsorption step of the process is conducted by passing the gas mixture through an adsorption zone containing type A zeolite whose exchangeable cations are preferably made up of at least about 60 but not more than 75% sodium ions and more than 25 and up to about 40 percent potassium ions.

Method of forming a (CFx)n containing adsorbent composition

A method of forming an adsorbent composition suitable for preferentially separating a fluorine-containing gas from a gas stream containing the same comprising: a) combining a (CF X ) n starting material with a non-fluorinated carbonaceous material wherein x in the starting (CF X ) n material is from about 0.6 to 1.2 and n is an integer, to form a mixture; b) exerting sufficient pressure on the mixture to form a shaped solid body; c) heating the shaped solid body to a temperature of at least 100°C to form a heated shaped solid body; and d) exposing the thus heated shaped solid body to a fluorine-containing gas under conditions sufficient to fluorinate the heated shaped solid body to produce a (CF X ) n final product wherein x is from about 0.5 to 1.2.

Hydrocarbon alkylation

A propene-enriched hydrocarbon fraction is alkylated by reaction with an i-butane enriched hydrocarbon fraction in an alkylation plant D. The propene-enriched fraction may be separated by adsorption from a hydrocarbon stream also containing propane in a separator A. A propane-enriched reaction containing i-butane is also produced in separator A. The i-butane-enriched fraction is separated from the propane-enriched fraction in a further separator B which may employ adsorption, distillation or membranes. In an alternative arrangement, a hydrocarbon stream containing propane, propene and i-butane is separated in separator B to form the i-butane-enriched hydrocarbon fraction and a propane-enriched fraction also containing propene, and the propane-enriched fraction has the propene-enriched fraction separated therefrom in separator A.

Process for the separation of alkenes and alkanes

Removal of carbon dioxide from gas streams

Carbon dioxide is removed from a gas stream by passing the gas stream through a bed of natural or synthetic clinoptilolite or their chemically-modified derivatives. This method is particularly advantageous when applied to the removal of ppm levels of carbon dioxide from gas streams at temperatures above 20°C, and finds application in the purification of air upstream of its separation by cryogenic distillation with preliminary refrigeration step upstream of the purification.

Removal of carbon dioxide from gas streams

Carbon dioxide is removed from gas streams comprised predominantly of gases that are less strongly adsorbed than is carbon dioxide by passing the gas stream through a bed of type X zeolite having a silicon to aluminum atomic ratio not greater than about 1.15 and at least 75% of the exchangeable cations of which are potassium ions, thereby adsorbing the carbon dioxide from the gas stream. The process is particularly advantageous when applied to the removal of low levels of carbon dioxide from gas streams at temperatures of about 0 to 80° C.

Removal of carbon dioxide from gas streams

Carbon dioxide is removed from a gas stream by passing the gas stream through a bed of natural or synthetic clinoptilolite or their chemically-modified derivatives. The process is particularly advantageous when applied to the removal of ppm levels of carbon dioxide from gas streams at temperatures above 20° C.

Temperature swing adsorption process

Antimalarial hexahydropyrimidine analogues

A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

Automatic syringe with priming mechanism

An air shot or priming mechanism for an injection pen. The injection pen comprises a cartridge-holder and a housing. The cartridge-holder interacts with a nut-member capable of driving the piston rod forward when relatively rotated. The cartridge-holder is rotational coupled to the housing such that rotation of the cartridge-holder relatively to the housing causes the nut-member and the piston rod to rotate relatively, thus the relative angular rotation between the cartridge-holder and the housing determines the size of the air shot so performed.

Gas separation process using composite or hollow adsorbent particles

A gas separation process comprising feeding a gaseous mixture comprising at least two components having different adsorption characteristics into an adsorption vessel containing at least one adsorbent material capable of preferentially adsorbing at least one of the gaseous components in the gaseous mixture and subjecting the gaseous mixture to non-cryogenic conditions which enable the preferentially adsorbable gaseous component in the gaseous mixture to adsorb onto the adsorbent material and separate from the non-adsorbed component in the gaseous mixture which pass through the adsorbent vessel wherein at least one adsorbent material in the adsorbent vessel comprises a composite particle having an inner core comprising a non-porous, non-adsorbent material and at least one outer layer comprising the adsorbent material. In another embodiment of the process of the present invention a hollow particulate adsorbent material is utilized.

Needle magazine

A needle magazine for holding a plurality of injection needles ( 50 ) is described. The needle magazine comprises a first opening adapted to receive the device fluid access portion ( 120 ) of a medical delivery device. Each needle ( 50 ) is selectively moveable from a respective storage position not aligned with said first opening into a needle mounting position aligned with said first opening. The needle magazine further comprises needle positioning means ( 41 ). configured to alter the mutual position between a needle selected from said plurality of needles ( 50 ) relative to a neighbor needle when said selected needle moves from its storage position to the needle mounting position.

Air purification process

Substantially all of the carbon dioxide is removed from a gas containing up to about 1% by volume carbon dioxide by subjecting the gas to a pressure swing adsorption process using as the adsorbent a single layer of zeolite having a silicon to aluminum atomic ratio in the range of 1.5 to 70. The process is particularly suitable for removing substantially all carbon dioxide and water vapor contained in air prior to subjecting the air to cryogenic distillation.

A collecting bag having an accommodating means for a closure device

The collecting bag comprises a bag member (1) formed by two film blanks (2, 3) with joined edges, and a discharge portion (6) comprising a discharge opening. A closure device (7) at the discharge portion (6) for bringing the bag from a discharge position, in which the bag is open, to a position of use, in which the bag is closed, is accommodated in accommodating means (8) in the position of use of the bag. The accommodating means (8) comprises at least one open receptacle formed in said bag member (1) and has a basis portion (9) in which said film blanks (2, 3) are undetachably connected to each other. The accommodating means may comprise a retaining element in the form of a strip (10) having at least one engagement section for releasable engagement with a corresponding section or corresponding sections on said bag member (1) or on the opposite end of said retaining element.

Tetrahydroimidazopyridine derivatives as modulators of tnf activity

A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Hydrocarbon alkylation process

A method of fixing a needle cannula in a radiation transmissive body

A metallic needle cannula is fixed inside a body by laser welding, whereby adhesives are not required. Metallic materials have large absorptions of all electromagnetic radiation, whereby a wider range of possible materials and wavelength is provided for the body and the radiation.

Adsorptive Separation of Nitrogen from Other Gases

Chabazite, offretite, erionite, levyne, mordenite, gmelinite, zeolite A, zeolite T, EMC-2, ZSM-3, ZSM-18, ZK-5, zeolite L, and beta zeolite whose exchangeable cations are composed of 95 to 50% lithium ions, 4 to 50% of one or more of aluminum, cerium, lanthanum and mixed lanthanides and 0 to 15% of other ions are prepared by ion-exchanging the base zeolite with water-soluble trivalent ionsalts and with water soluble lithium salts. The zeolites preferentially adsorb nitrogen from gas mixtures.

Apparatus for thermally bonding plastics foils and method of operating the same

Tnf -alpha modulating benz imidazoles

A compound of formula (IIB): (see formula IIB) wherein E represents -N(R4)-, -CH2-, -CH(CH3)- or -CH(CH2CH3)-; Q represents -CH2-, -CH2O-, -CH2S- or -CH2OCH2-; Z represents hydrogen, fluoro or an organic radical (unsubstituted or substituted, linear, cyclic or aromatic, and eventually interrupted by at least one heteroatom); V represents C-R22 or N; R4 represents hydrogen or C1-6 alkyl; R12 represents hydrogen, fluoro, chloro, trifluoromethyl or methyl; R15 and independently represent hydrogen, halogen, cyano, nitro, or an organic radical (unsubstituted or substituted, linear, cyclic or aromatic, and eventually interrupted by at least one heteroatom); R21 represents hydrogen, halogen, cyano or an organic radical (unsubstituted or substituted, linear, cyclic or aromatic, and eventually interrupted by at least one heteroatom); R22 represents hydrogen, halogen or C1-6 alkyl; and R23 represents hydrogen or C1-6 alkyl. A pharmaceutical composition comprising said compound of formula (IIB). Useful in the treatment and/or prevention of various human ailments.

Removal of carbon dioxide from gas streams

Flexographic printer and printing process using a colour space that can be printed using CMYK inks

A flexographic printing apparatus 1 for recreating at least one color from at least 1000 spot colours on to a substrate 12 using only the CMYK inks comprises: at least one ink reservoir 2; a plate cylinder 8 comprising a flexographic plate; at least one meter roll 6; an impression cylinder 10 for sandwiching a substrate 12 between the impression cylinder 10 and the flexographic plate to transfer the ink thereon to the substrate; wherein the flexographic plate comprises a plurality of flat top dots. The meter roll 6 is preferably an anilox roller. The invention further relates to a flexographic printing process for recreating at least one colour from a group of at least 1000 spot colors on to a substrate using only the CMYK inks and to a CIELab colour space obtainable by said process.

Oxygen sorbent compositions and methods of using same

Compositions and methods useful for oxygen sorption and other uses are presented within the general formulas (1), (2), (3), (4), (5), (6), and (7): A 2 BO 4−δ (1) A 2 B 2 O 5−δ (2) AO(ABO 3−δ ) n (3) AM 2 Cu 3 O 7−δ (4) Bi 4 V 2(1−x) Me 2x O 11−3x , (5) A′B′O 3 where B′ is W or Mo; (6) A 2 B 2 O 7−δ , (7) and combinations thereof, wherein: A is a cation of atoms having atomic numbers ranging from 57-71, inclusive, a cation of yttrium, cations of Groups 1 and 2 atoms, and combination thereof; B is a cation of a d-block transition metal; A′ is a cation of Na or Li; M is a metal cation selected from cations of Group 2 atoms; Me is a metal cation of Cu, Bi, and Co atoms; x ranges from 0.01 to 1.00; and δ ranges from 0.05 to 0.30. The compounds (1)-(7) may function as active supports for binary metal oxides to enhance the oxygen sorption/desorption capacity of the composites.

Method and vessel for the storage of gas

Acetylene is stored at elevated pressure by charging with acetylene at elevated pressure a pressure vessel (typically a gas cylinder) containing carbonaceous adsorbent able reversibly to adsorb acetylene. The adsorbent has: a) a specific micropore volume equal to or greater than 0.5 cm3/g; b) a specific mesopore volume equal to or greater than 0.5 cm3/g; c) a bulk density equal to or greater than 0.25 g/cm3; and d) a surface area per volume equal to or greater than 400 m2/cm3. Alternatively or in addition to (a) and (b) above the specific volume of pores having a diameter in the range of 1.5 to 3.0 nm is equal to or greater than 0.3 cm3/g, but the sum of the specific mesopore volume and the specific micropore volume should always be equal to or greater than 1.0 cm3/g. Preferably, at least 75 % of the specific mesopore volume is contributed by mesopores having a diameter in the range of 2 to 5 nm and at least 90 % of the micropores have a diameter of at least 0.4 nm. The absorbent is typically in a free flowing or monolithic form.

Removal of carbon dioxide from (air) gases by adsorption onto clinoptilolite; high purity nitrogen and oxygen from air

Adsorptive separation of nitrogen from other gases

Chabazite, offretite, erionite, levyne, mordenite, gmelinite, zeolite A, zeolite T, EMC-2, ZSM-3, ZSM-18, ZK-5, zeolite L, and beta zeolite whose exchangeable cations are composed of 95 to 50% lithium ions, 4 to 50% of one or more of aluminum, cerium, lanthanum and mixed lanthanides and 0 to 15% of other ions are prepared by ion-exchanging the base zeolite with water-soluble trivalent ionsalts and with water soluble lithium salts. The zeolites preferentially adsorb nitrogen from gas mixtures.

Imidazopyridine derivatives as modulators of TNF activity

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Adsorptive separation of nitrogen from other gases

Temperature swing adsorption process

Nitrogen oxides and low molecular weight hydrocarbons are removed from air by subjecting the air to a temperature swing adsorption process using as the adsorbent a composite zeolite product containing both zeolite A and zeolite X. The composite zeolite product is preferably prepared by forming a mixture of an agglomerate of silica and sodium zeolite X having a Si/Al atomic ratio in the range of about 0.9 to less than about 1.2 and a water-soluble sodium aluminate salt; maintaining the mixture at a temperature in the range of about 25 to about 100° C. for a period of time sufficient to convert at least 50% of the silica to sodium zeolite A; and at least partially exchanging the zeolite A-containing product with divalent cations, preferably calcium ions.

Method of manufacture of multicationic molecular sieves

Zeolites exchanged with lithium cations and polyvalent cations are prepared by first partially ion-exchanging a sodium-containing zeolite, a potassium-containing zeolite or a sodium- and potassium-containing zeolite with polyvalent cations, then heat-treating the partially polyvalent cation-exchanged zeolite, then ion exchanging the heat-treated zeolite with ammonium cations, and then reacting the ammonium cation-exchanged zeolite with a water-soluble lithium compound under conditions which result in the removal of ammonia from the reaction zone.

Thermal swing adsorption process

A method of removing adsorbate and device for carrying out this method

A method of removing an adsorbate from a stream (A) includes the steps of: passing said stream through an adsorbent thereby to adsorb said adsorbate; regenerating said adsorbent by passing a second stream containing a more readily adsorbed adsorbate therethrough such that the more readily adsorbed adsorbate replaces said first adsorbate; and passing a third stream, having a lower concentration of said more readily adsorbed adsorbate than said second stream, through said adsorbent thereby to desorb said more readily adsorbed adsorbate and preparing it for adsorption of said first adsorbate. <IMAGE>

Coated glass.

Bent and/or toughened silver coated glass having high light transmission and low emissivity is produced by depositing layers of additional metal over, or both under and over, the silver layer. When the additional metal is used over the silver layer, it is selected from aluminium, titanium, zinc and tantalum. When the additional metal is used both under and over the silver, it is selected from aluminium, titanium, zinc, tantalum and zirconium. The additional metal is used in an amount such that the light transmission of the coated glass increases on bending and/or toughening. The bent and/or toughened coated glass is useful for architectural glazing and as vehicle windows.

Method and apparatus for filling containers with gas mixtures

Gas cylinders are filled with mixtures of gases comprising a minor component, which is to be present in the mixture at a concentration of 10% or less of the total volume of the cylinder, and a major component, which is to be present at a concentration greater than about 10% of the total volume, by charging the lighter component into a chamber of given volume to a pressure and at a temperature such that the volume provides the desired fraction of minor component in the gas mixture, and then flushing the minor component into the cylinder using major component gas as the flushing agent. The pressure at which the minor component volume is to be measured is preferably at or near the final pressure of the filled gas cylinder.

Improved adsorbent compositions

An adsorbent composition, which is comprised by both an active adsorbent component and an active thinner component, is disclosed. The active thinner component will range in weight from about 5 % to about 80 % of the composition. The adsorbent composition is useful in separating a gas component from a gas mixture such as in cyclic adsorption processes.

Adsorbents and adsorptive separation process

Adsorbent composites composed of microparticulate zeolites at least 90% of whose particles have a characteristic particle dimension not greater than about 0.6 micron and a macropore inert binder. The composites are useful for separating strongly adsorbed gas components from gas mixtures. Microparticulate type X zeolites composites are particularly useful for separating nitrogen or carbon dioxide from air.

A collecting bag for human body wastes

The collecting bag comprises a bag member (1) formed by two film blanks with joined edges, an inlet opening being provided in one of said film blanks surrounded by connecting elements for connection of the bag to a body orifice. The bag is emptied through a narrowed, elongated discharge portion (8) ending in a discharge opening (9). Sealing plates (35a, 35b) made from a resilient material, e.g. foam, are attached to the discharge portion (8) at or near the discharge opening (9) to close the discharge opening by folding of the discharge portion (8).

Wave power device

The present invention relates to a wave power device for extracting energy from water waves. The waver power device comprise a reference structure and effectors moving relative to the reference structure. The effectors are connected to two hydraulic rams, symmetrically positioned around each effector. The hydraulic rams have an effective hydraulic area which is stepwise increased as the length of the hydraulic rams are compressed and stepwise increased as the length of the hydraulic rams are increased.

COATED GLASS.

Bent and/or toughened silver coated glass having high light transmission and low emissivity is produced by depositing layers of additional metal over, or both under and over, the silver layer. When the additional metal is used over the silver layer, it is selected from aluminium, titanium, zinc and tantalum. When the additional metal is used both under and over the silver, it is selected from aluminium, titanium, zinc, tantalum and zirconium. The additional metal is used in an amount such that the light transmission of the coated glass increases on bending and/or toughening. The bent and/or toughened coated glass is useful for architectural glazing and as vehicle windows.

CONTROL SYSTEM WITH COMPUTER.

A computer control system, especially a flight control computer system, comprises a series of computer modules operating in parallel and asynchronously to carry out respective parts of an overall control algorithm for a series of items to be controlled, each computer module having a data transmission port connected via a broadcast line to a respective input port of each other computer module so that communication between modules is achieved by any of the modules broadcasting asynchronous data messages onto its broadcast line for the messages to be received by any other modules which require them.

Hydrocarbon alkylation process

A hydrocarbon stream is cracked to produce a hot gaseous stream which is compressed and cooled to condense almost all of the hydrocarbons contained in the stream. A noncondensed stream remaining after the condensation step, comprised predominantly of hydrogen and C1 to C3 hydrocarbons, is subjected to pressure swing adsorption or temperature swing adsorption at an adsorption temperature of about 0 to about 250° C in a bed of adsorbent which selectively adsorbs ethene and propene, thereby adsorbing substantially all of the ethene and propene from the gas stream. The ethene and/or propene is recovered upon bed regeneration. Higher alkenes are separated from alkanes by various methods.

An ostomy plug

A disposable closure for a natural or artificial intestinal or urethral opening in the form of a body made from a material being soluble in visceral contents provides a disposable closure for a natural or artificial intestinal or urethral opening which closure is easy to apply, provides a proper sealing and is readily removed after having exercised its effect.

Adsorbate removal

A method of removing an adsorbate from a stream (A) includes the steps of: passing said stream through an adsorbent thereby to adsorb said adsorbate; regenerating said adsorbent by passing a second stream containing a more readily adsorbed adsorbate therethrough such that the more readily adsorbed adsorbate replaces said first adsorbate; and passing a third stream, having a lower concentration of said more readily adsorbed adsorbate than said second stream, through said adsorbent thereby to desorb said more readily adsorbed adsorbate and preparing it for adsorption of said first adsorbate.

Mechanism for oscillating a sample holder within a sample vessel

A mechanism used in connection with determining a time resolved interaction between a target substance, for instance, an adsorbent and at least one agent, for instance, an adsorbate capable of interacting with the target substance. In accordance with the method the target substance and agent(s) are introduced into a sample vessel. At the same time, the target substance is oscillated within the sample vessel without changing the volume of the sample vessel. A concentration of one or more components associated with the time resolved interaction as a function of time is measured by measuring chamber pressure and simultaneously performing a mass spectroscopical analysis of chamber content at discrete time intervals. The target substance is oscillated by a mechanical movement which oscillates a sample holder configured to hold the target substance. The movement has a finger-like member, preferably formed by welded steel bellows and a curved member rotating within the finger-like member so that motion of the finger-like member does not change chamber volume and therefore effect the pressure measurements that are to be made in accordance with the method.

Separation of nitrogen from other gases by adsorption.

Process for the purification of nitric oxide

A gas mixture comprised of nitric oxide and, optionally an inert gas, and containing small amounts of nitrogen dioxide, and perhaps moisture and sulfur dioxide, is purified by passing the gas stream through a bed of metal cation-free alumina-deficient zeolites of types Y or ZSM-5. The concentrations of nitrogen dioxide, sulfur dioxide and moisture in the gas stream are reduced to about 1 ppm or less as the gas mixture passes through the bed of zeolite.

Tnf -alpha modulating benzimidazoles

A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused pentacyclic imidazole derivatives as modulators of tnf activity

A series of substituted fused pentacyclic benzimidazole derivatives,and analogues thereof,being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Injection device with visual end-of-content indication

An injection device ( 1 ) with an End-of-Content mechanism. The End-of-Content mechanism comprises a track ( 91 ) and a track follower each coupled directly or indirectly to the housing and the dose setting member ( 20 ). When setting a dose, the housing and the dose setting member is rotated relatively to each other thereby also rotating the track-follower in the track a distance corresponding to the size of the set dose. This relative rotation is summarized and stored in the position of the track follower in the track. The housing containing the mechanism is preferably equipped with a transparent ( 71 ) area through which a user can inspect the position of the track follower in the track and thereby get a visible warning when the drug reservoir in the injection device is about to be emptied.

Thermal swing adsorption process for the removal of dinitrogen oxide, hydrocarbons and other trace impurities from air

The present invention provides for a process for purifying atmospheric air prior to its separation by cryogenic distillation. The process utilizes three adsorbent layers, the first primarily removes water; the second primarily removes CO 2 ; and the third layer is designed to remove displaced gas components such as N 2 O and hydrocarbons which are displaced by the second layer. It has been found that CaX type adsorbents provide the removal of N 2 O and hydrocarbons in the third layer.

AN OSTOMY APPARATUS

Un aparato de ostomía que comprende una pared delantera y una pared trasera de material flexible que forman una bolsa, teniendo la pared trasera una abertura en la bolsa por la que puede entrar el material de desecho en la bolsa y una de las paredes tiene uno o más orificios por los que puede escapar el gas de la bolsa y que tiene un filtro que tapa dicho orificio, en el que las aberturas de entrada (10) y salida (11) de gas se proporcionan en comunicación con un cuerpo de filtro (5), siendo la disposición tal que en uso el gas fluye a través del filtro de la abertura de entrada a la abertura de salida, confinándose tal flujo de gas en dicho cuerpo de filtro, caracterizado porque la abertura de entrada de gas al filtro está provista de al menos dos pasos cerrados separados e independientes (18, 19) que tienen aberturas de entrada separadas (16) que comunican con la bolsa y aberturas de salida separadas e independientes que comunican con la abertura de entrada del filtro y en el que cada unade las aberturas de salida de los pasos separados está tapada por una membrana microporosa (12). An ostomy apparatus comprising a front wall and a rear wall of flexible material forming a bag, the rear wall having an opening in the bag through which the waste material can enter the bag and one of the walls has one or more holes through which gas can escape from the bag and which has a filter that covers said hole, in which the gas inlet (10) and gas outlet (11) openings are provided in communication with a filter body (5 ), the arrangement being such that in use the gas flows through the filter from the inlet opening to the outlet opening, such gas flow being confined in said filter body, characterized in that the gas inlet opening to the filter is provided of at least two separate and independent closed passages (18, 19) that have separate inlet openings (16) that communicate with the separate and independent outlet bag and openings that communicate with the inlet opening of the ...

Antimalarial hexahydropyrimidine analogues

A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

An ostomy appliance

An ostomy appliance comprising a front wall and a rear wall of flexible material forming a bag, the rear wall having an opening into the bag by which waste material can enter the bag and one of the walls has one or more vents through which gas may escape from the bag and having a filter covering said vent wherein gas inlet and outlet openings and provided in communication with a filter body, the arrangement being so that in use gas flows through the filter from the inlet opening to the outlet opening, such gas flo w being confined to said filter body, wherein the gas inlet opening to the filter is provided with at least two separate and independent closed pathways having separated inlet openings communicating with the bag and separate and independent outlet openings communicating with the inlet opening of the filter, and wherein each of the outlet openings of the separate pathways are covered by a microporous membrane shows improved resistance against blocking of the inlet opening of filter.

Type x zeolite most cations are lithium, a large proportion are trivalent cations, and optionally some residual cations; separation of nitrogen by adsorption

ZEOLITES AND THEIR USE IN THE SEPARATION OF GASEOUS MIXTURES.

SE PRESENTAN ZEOLITAS DE TIPO X CUYOS CATIONES DE COMPENSACION DE CARGA ESTAN COMPUESTOS SOBRE UNA BASE DE EQUIVALENTES DE ENTRE UN 95 Y UN 50% DE IONES DE LITIO, ENTRE UN 4 Y UN 50% DE UNO O MAS DE ENTRE ALUMINIO, CERIO, LANTANO Y LANTANIDOS MEZCLADOS Y ENTRE UN 0 Y UN 15% DE OTROS IONES. LAS ZEOLITAS ABSORBEN PREFERENCIALMENTE NITROGENOS DE MEZCLAS DE GAS. LAS ZEOLITAS EXHIBEN UNA ESTABILIDAD TERMICA SUPERIOR Y PROPIEDADES DE ABSORCION DE NITROGENO. PUEDEN PREPARARSE MEDIANTE INTERCAMBIO DE IONES. TYPE X ZEOLITES ARE PRESENT WHOSE LOAD COMPENSATION CATIONS ARE COMPOSED ON A BASIS OF EQUIVALENTS OF BETWEEN 95 AND 50% OF LITHIUM IONS, BETWEEN 4 AND 50% OF ONE OR MORE BETWEEN ALUMINUM, CERIO, LANTAN AND MIXED LANTANIDES AND BETWEEN 0 AND 15% OF OTHER IONS. ZEOLITES PREFERABLY ABSORB NITROGENS FROM GAS MIXTURES. ZEOLITES EXHIBIT SUPERIOR THERMAL STABILITY AND NITROGEN ABSORPTION PROPERTIES. THEY CAN BE PREPARED THROUGH ION EXCHANGE.

Coated glass

ABSTRACT Coated Glass Bent and/or toughened silver coated glass having high light transmission and low emissivity is produced by depositing layers of additional metal over, or both under and over, the silver layer. When the additional metal is used over the silver layer, it is selected from aluminium, titanium, zinc and tantalum. When the additional metal is used both under and over the silver, it is selected from aluminium, titanium, zinc, tantalum and zirconium. The additional metal is used in an amount such that the light transmission of the coated glass increases on bending and/or toughening. The bent and/or toughened coated glass is useful for architectural glazing and as vehicle windows.

Apparatus for converting ocean wave energy

The purpose of this invention is to present a device for utilisation of the horizontal component of wave motions in which there is no proportionality between the installed power and the initial costs of the device. According to the invention, this is obtained with a device which contains at least one oblong supporting structure and three or more independently movable resis-tance elements.

TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

DERIVADOS DE TETRA-HIDROIMIDAZOPIRIDINA COMO MODULARES DE ATIVIDADE DE TNF. Trata-se de uma série de derivados de 4,5,6,7-tetra-hidro-3H-imidazo[4,5-c]piridina substituídos de fórmula (I), que são moduladores potentes da atividade de TNF(Alfa) humano, que são, consequentemente, benéficos no tratamento e/ou prevenção de várias enfermidades humanas, incluindo distúrbios inflamatórios ou autoimunes; distúrbios neurológicos e neurodegenerativos; dor e distúrbios nociceptivos; distúrbios cardiovasculares; distúrbios metabólicos; distúrbios oculares; e distúrbios oncológicos. TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULARS OF TNF ACTIVITY. These are a series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), which are potent modulators of TNF(Alpha) activity human, which are consequently beneficial in the treatment and/or prevention of various human diseases, including inflammatory or autoimmune disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; eye disorders; and oncological disorders.

Hydrocarbon alkylation process

Oxygen sorbent compositions and methods of using same

Composites and methods useful for oxygen sorption and other uses are presented, the composites comprising: (A) one or more crystalline ceramic oxides selected from compounds within general formula (1): A x A′ x′ B y B′ y′ O 3-δ   (1) and (B) one or more crystalline ceramic oxides selected from compounds within general formulas (2), (3), (4), (5), (6), (7), and (8): A 2 BO 4-δ   (2) A 2 B 2 O 5-δ   (3) AO(ABO 3-δ ) n   (4) AM 2 Cu 3 O 7-δ   (5) Bi 4 V 2(1-x) Me 2x O 11-3x ,   (6) A″B″O 3   (7) A 2 B 2 O 7-δ   (8)

Fused thiophene derivatives as mek inhibitors

A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

Method and vessel for the storage of gas

A needle magazine

A needle magazine for holding a plurality of injection needles (50) is described. The needle magazine comprises a first opening adapted to receive the device fluid access portion (120) of a medical delivery device. Each needle (50) is selectively moveable from a respective storage position not aligned with said first opening into a needle mounting position aligned with said first opening. The needle magazine further comprises needle positioning means (41). configured to alter the mutual position between a needle selected from said plurality of needles (50) relative to a neighbour needle when said selected needle moves from its storage position to the needle mounting position.

COATED GLASS

La presente invención se refiere a procedimiento para la producción de un substrato de vidrio revestido con plata, curvado y/o templado, caracterizado porque comprende someter un substrato de vidrio con un revestimiento que comprende una capa de plata con un espesor de 5 nm a 30 nm, una capa de metal adicional seleccionada de aluminio, titanio, zinc y tantalio, sobre la capa de plata, y una capa de óxido metálico anti-reflexión sobre la capa de metal adicional, a un ciclo de curvado y/o templado, en el que se calienta a una temperatura por encima del punto de ablandamiento del vidrio, con lo que el vidrio revestido desarrollo una transmisión a la luz incrementada durante el ciclo de curvado y/o templado.

Purification of natural gas

Purification of natural gas

Natural gas liquids and water vapor are removed from natural gas by a series of steps. In one embodiment the natural gas liquids and water vapor are removed by passing the natural gas first through a bed of aluminum-deficient zeolite to remove the natural gas liquids, then through a bed of water-selectiveadsorbent. In another embodiment, a combination of an aluminum-deficient adsorbent and an absorption system are used to remove the natural gas liquids and water vapor from the natural gas.

Adsorbents and adsorptive separation process

Novel compositions of molecular sieve adsorbents are provided in which at least 50% of the exchangeable cations are selected from those of Li, Ca, Ag and Cu and which have within their pore system metal oxide, metal oxide precursors or mixtures thereof. These compositions are useful for the separation of gases and, in particular, the separation of nitrogen from air to produce oxygen or oxygen-enriched gas.

Method and vessel for the storage of gas

Acetylene is stored at elevated pressure by charging with acetylene at elevated pressure a pressure vessel (typically a gas cylinder) containing carbonaceous adsorbent able reversibly to adsorb acetylene. The adsorbent has: a) a specific micropore volume equal to or greater than 0.5 cm3/g; b) a specific mesopore volume equal to or greater than 0.5 cm3/g; c) a bulk density equal to or greater than 0.25 g/cm3; and d) a surface area per volume equal to or greater than 400 m2/cm3. Alternatively or in addition to (a) and (b) above the specific volume of pores having a diameter in the range of 1.5 to 3.0 nm is equal to or greater than 0.3 cm3/g, but the sum of the specific mesopore volume and the specific micropore volume should always be equal to or greater than 1.0 cm3/g. Preferably, at least 75 % of the specific mesopore volume is contributed by mesopores having a diameter in the range of 2 to 5 nm and at least 90 % of the micropores have a diameter of at least 0.4 nm. The absorbent is typically in a free flowing or monolithic form.

Bendable and/or toughenable silver coatings on glass

Bent and/or toughened silver coated glass having high light transmission and low emissivity is produced by depositing layers of additional metal over, or both under and over, the silver layer. When the additional metal is used over the silver layer, it is selected from aluminium, titanium, zinc and tantalum. When the additional metal is used both under and over the silver, it is selected from aluminium, titanium, zinc, tantalum and zirconium. The additional metal is used in an amount such that the light transmission of the coated glass increases on bending and/or toughening. The bent and/or toughened coated glass is useful for architectural glazing and as vehicle windows.

Temperature swing adsorption process

Nitrogen oxides and low molecular weight hydrocarbons are removed from air by subjecting the air to a temperature swing adsorption process using as the adsorbent a composite zeolite product containing both zeolite type A and zeolite type X. The composite zeolite product is prepared by crystallizing a sodium ion- or sodium ion- and potassium ion-containing alumina-silica hydrogel under conditions which result in the production of a zeolitic composite which contains both zeolite type A and zeolite type X crystal domains. In a preferred embodiment, calcium ions constitute a substantial number of the composite's exchangeable cations and the type X portion of the composite zeolite product has a silicon-to-aluminum atomic ratio in the range of 0.9 to less than 1.15. The nitrogen oxide- and hydrocarbon-selective adsorbent can be incorporated into an atmospheric air prepurification plant downstream of a water vapor-selective adsorbent and a carbon dioxide-selective adsorbent.

A method of fixing a needle cannula in a radiation transmissive body

A metallic needle cannula is fixed inside a body by laser welding, whereby adhesives are not required. Metallic materials have large absorptions of all electromagnetic radiation, whereby a wider range of possible materials and wavelength is provided for the body and the radiation.

Process for making coated glass and product according to this process

Ostomy appliance coupling system and an ostomy appliance

According to an embodiment of the invention, an ostomy appliance coupling system is disclosed. The system comprises a wafer part having a rise extending away from a body surface to form a guide means and a shallow landing zone; a pouch part having a guide adapted to engage with the landing zone in a desired location relative to the guide means; and an adhesive layer recessed within the guide and adapted to adhere to the landing zone.

Composite adsorbent beads for adsorption process

A gas separation process comprising feeding a gaseous mixture comprising at least two components having different adsorption characteristics into an adsorption vessel containing at least one adsorbent material capable of preferentially adsorbing at least one of the gaseous components in the gaseous mixture and subjecting the gaseous mixture to non-cryogenic conditions which enable the preferentially adsorbable gaseous component in the gaseous mixture to adsorb onto the adsorbent material and separate from the non-adsorbed component in the gaseous mixture which pass through the adsorbent vessel wherein at least one adsorbent material in the adsorbent vessel comprises a composite particle having an inner core comprising a non-porous, non-adsorbent material and at least one outer layer comprising the adsorbent material. In another embodiment of the process of the present invention a hollow particulate adsorbent material is utilized.

Pharmaceutical 6,5 heterobicyclic ring derivatives

The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.

Adsorbent compositions

An ostomy appliance

An ostomy appliance comprising a front wall and a rear wall of flexible material forming a bag, the rear wall having an opening into the bag by which waste material can enter the bag and one of the walls has one or more vents through which gas may escape from the bag and having a filter covering said vent wherein gas inlet and outlet openings and provided in communication with a filter body, the arrangement being so that in use gas flows through the filter from the inlet opening to the outlet opening, such gas flo w being confined to said filter body, wherein the gas inlet opening to the filter is provided with at least two separate and independent closed pathways having separated inlet openings communicating with the bag and separate and independent outlet openings communicating with the inlet opening of the filter, and wherein each of the outlet openings of the separate pathways are covered by a microporous membrane shows improved resistance against blocking of the inlet opening of filter.

Adsorptive Separation of Nitrogen from Other Gases

Type X zeolites whose charge-compensating cations are composed of 95 to 50% lithium ions, 4 to 50% of one or more of aluminum, cerium, lanthanum and mixed lanthanides and 0 to 15% of other ions. The zeolites preferentially adsorb nitrogen from gas mixtures.

Injection device with visual end-of-content indication

An injection device ( 1 ) with an End-of-Content mechanism. The End-of-Content mechanism comprises a track ( 91 ) and a track follower each coupled directly or indirectly to the housing and the dose setting member ( 20 ) . When setting a dose, the housing and the dose setting member is rotated relatively to each other thereby also rotating the track-follower in the track a distance corresponding to the size of the set dose. This relative rotation is summarized and stored in the position of the track follower in the track. The housing containing the mechanism is preferably equipped with a transparent ( 71 ) area through which a user can inspect the position of the track follower in the track and thereby get a visible warning when the drug reservoir in the injection device is about to be emptied.

Tetrahydroimidazopyridine derivatives as modulators of tnf activity

A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Method of manufacture of molecular sieves

Zeolites exchanged with lithium ions and, optionally polyvalent cations are prepared by ion-exchanging a sodium-containing zeolite, a potassium-containing zeolite or a sodium- and potassium-containing zeolite with ammonium ions, thereby replacing the sodium and/or potassium ions with ammonium ions, and then reacting the ammonium ion-exchanged zeolite with a water-soluble lithium compound under conditions which result in the removal of ammonia from the reaction zone. Polyvalent ions, which may be present in the zeolite undergoing ion-exchange, will not be substantially replaced by the ammonium or lithium ions.

Mechanism for oscillating a sample holder within a sample vessel

A mechanism used in connection with determining a time resolved interaction between a target substance, for instance, an adsorbent and at least one agent, for instance, an adsorbate capable of interacting with the target substance. In accordance with the method the target substance and agent(s) are introduced into a sample vessel. At the same time, the target substance is oscillated within the sample vessel without changing the volume of the sample vessel. A concentration of one or more components associated with the time resolved interaction as a function of time is measured by measuring chamber pressure and simultaneously performing a mass spectroscopical analysis of chamber content at discrete time intervals. The target substance is oscillated by a mechanical movement which oscillates a sample holder configured to hold the target substance. The movement has a finger-like member, preferably formed by welded steel bellows and a curved member rotating within the finger-like member so that motion of the finger-like member does not change chamber volume and therefore effect the pressure measurements that are to be made in accordance with the method.

Nlrp3 modulators

Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of NLRP3 and/or the NLRP3 inflammasome. Such compounds are represented by Formula (I), wherein the variables are defined herein.